MedTrace Logo

Trial to Assess the Safety and Clinical Performance of Contino® in Preventing Urinary Incontinence

NCT04165408 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-02-20

No results posted yet for this study

Summary

This trial is to assess the safety and clinical performance of Contino device is preventing Urinary Incontinence in male subjects with Sphincteric Incompetence

Conditions

Interventions

DEVICE

Contino

The Contino® urethral insert is a self-administered licensed medical device, is inserted into the distal portion of the male urethra inhibiting the flow of urine. The Contino is self-inserted into the adult male urethra and is removed prior to urination. Much more than just a device, Contino® is an integrated solution that includes personalised fitting and support from incontinence specialists. It is made from highly specialised medical grade polymer, which has been extensively tested for biocompatibility.

Sponsors & Collaborators

  • CMX Research

    lead OTHER

Principal Investigators

  • Dean Elterman, MD · University Urology Associates

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-19
Primary Completion
2025-09-01
Completion
2025-12-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04165408 on ClinicalTrials.gov